PL373511A1 - Zasadniczo homogeniczny biooddziaływujący materiał o wstępnie określonym stosunku składnika biooddziaływującego do składnika ukierunkowanego komórkowo, sposób wytwarzania takiego materiału oraz sposób jego stosowania - Google Patents
Zasadniczo homogeniczny biooddziaływujący materiał o wstępnie określonym stosunku składnika biooddziaływującego do składnika ukierunkowanego komórkowo, sposób wytwarzania takiego materiału oraz sposób jego stosowaniaInfo
- Publication number
- PL373511A1 PL373511A1 PL02373511A PL37351102A PL373511A1 PL 373511 A1 PL373511 A1 PL 373511A1 PL 02373511 A PL02373511 A PL 02373511A PL 37351102 A PL37351102 A PL 37351102A PL 373511 A1 PL373511 A1 PL 373511A1
- Authority
- PL
- Poland
- Prior art keywords
- component
- making
- molecules
- bioaffecting
- drug
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 230000008685 targeting Effects 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 4
- 229940079593 drug Drugs 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29068401P | 2001-05-15 | 2001-05-15 | |
| US32953501P | 2001-10-17 | 2001-10-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL373511A1 true PL373511A1 (pl) | 2005-09-05 |
Family
ID=26966358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL02373511A PL373511A1 (pl) | 2001-05-15 | 2002-05-15 | Zasadniczo homogeniczny biooddziaływujący materiał o wstępnie określonym stosunku składnika biooddziaływującego do składnika ukierunkowanego komórkowo, sposób wytwarzania takiego materiału oraz sposób jego stosowania |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20040167061A1 (pl) |
| EP (1) | EP1414299B1 (pl) |
| JP (1) | JP2005514322A (pl) |
| CN (1) | CN1307200C (pl) |
| AT (1) | ATE507844T1 (pl) |
| CA (1) | CA2447391C (pl) |
| DE (1) | DE60239938D1 (pl) |
| PL (1) | PL373511A1 (pl) |
| WO (1) | WO2002091991A2 (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004532245A (ja) | 2001-05-15 | 2004-10-21 | ページ ダブル フォーク | 癌を治療するための生体影響性化合物の標的送達 |
| ATE333288T1 (de) | 2001-05-15 | 2006-08-15 | Faulk Pharmaceuticals Inc | Gezielte freisetzung von arzneimitteln zur behandlung von virusinfektionen |
| CA2447395A1 (en) * | 2001-05-16 | 2002-11-21 | Faulk Pharmaceuticals, Inc. | Targeted delivery of drugs for the treatment of parasitic infections |
| WO2003032899A2 (en) * | 2001-10-17 | 2003-04-24 | Faulk Pharmaceuticals, Inc | Methods and materials for targeting and affecting selected cells |
| EP2531173B1 (en) * | 2010-02-03 | 2018-09-26 | Oncbiomune, L.L.C. | Taxane- and taxoid-protein compositions |
| JP5378469B2 (ja) * | 2011-08-11 | 2013-12-25 | 学校法人 日本歯科大学 | 医療用薬剤 |
| KR20140048404A (ko) * | 2012-10-11 | 2014-04-24 | 포항공과대학교 산학협력단 | 저밀도 지단백질 유사 나노입자 및 이를 포함하는 간 표적 진단 및 치료용 조성물 |
| EP4637829A1 (en) * | 2022-12-20 | 2025-10-29 | Cellis Sp. z o.o. ([Ltd.] | Isolated targeted delivery system for the treatment of ovarian cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US28686A (en) * | 1860-06-12 | Improvement in steam-radiators | ||
| GB2116979B (en) * | 1982-02-25 | 1985-05-15 | Ward Page Faulk | Conjugates of proteins with anti-tumour agents |
| JPH0720886B2 (ja) * | 1983-08-10 | 1995-03-08 | ペ−ジ フオ−ク，ウオ−ド | タンパク質と抗腫瘍剤との複合体 |
| GB8519457D0 (en) * | 1985-08-02 | 1985-09-11 | Faulk Ward Page | Tumour imaging agents |
| US5264373A (en) * | 1987-02-17 | 1993-11-23 | Abbott Laboratories | Fluorescence polarization immunoassay for tetrahydrocannabinoids |
| US5208323A (en) * | 1989-08-10 | 1993-05-04 | Universite Laval | Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent |
| US5393737A (en) * | 1992-08-20 | 1995-02-28 | Health Research, Inc. | Cytotoxic drug conjugates for treatment of neoplastic diseases |
| CA2168647A1 (en) * | 1993-08-02 | 1995-02-09 | Barbara A. Sosnowski | Monogenous preparations of cytotoxic conjugates |
| ATE225799T1 (de) * | 1994-04-08 | 2002-10-15 | Receptagen Corp | Rezeptor modulierendes mitteln und entsprechendes verfahren |
| DE19636889A1 (de) * | 1996-09-11 | 1998-03-12 | Felix Dr Kratz | Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel |
| US6020316A (en) * | 1997-09-25 | 2000-02-01 | Lanks; Karl W. | Glutaraldehyde modified chemotherapeutic agents and methods of use thereof |
| JP2002095476A (ja) * | 2000-09-20 | 2002-04-02 | Eisai Co Ltd | トランスフェリン受容体を介した遺伝子導入法 |
| WO2002076448A1 (en) * | 2001-03-23 | 2002-10-03 | Napro Biotherapeutics, Inc. | Molecular conjugates for use in treatment of cancer |
| JP2004532245A (ja) * | 2001-05-15 | 2004-10-21 | ページ ダブル フォーク | 癌を治療するための生体影響性化合物の標的送達 |
| CA2447395A1 (en) * | 2001-05-16 | 2002-11-21 | Faulk Pharmaceuticals, Inc. | Targeted delivery of drugs for the treatment of parasitic infections |
| WO2003032899A2 (en) * | 2001-10-17 | 2003-04-24 | Faulk Pharmaceuticals, Inc | Methods and materials for targeting and affecting selected cells |
-
2002
- 2002-05-15 PL PL02373511A patent/PL373511A1/pl not_active Application Discontinuation
- 2002-05-15 DE DE60239938T patent/DE60239938D1/de not_active Expired - Lifetime
- 2002-05-15 US US10/477,999 patent/US20040167061A1/en not_active Abandoned
- 2002-05-15 JP JP2002588910A patent/JP2005514322A/ja active Pending
- 2002-05-15 AT AT02736574T patent/ATE507844T1/de not_active IP Right Cessation
- 2002-05-15 EP EP02736574A patent/EP1414299B1/en not_active Expired - Lifetime
- 2002-05-15 CA CA2447391A patent/CA2447391C/en not_active Expired - Fee Related
- 2002-05-15 CN CNB028142403A patent/CN1307200C/zh not_active Expired - Fee Related
- 2002-05-15 WO PCT/US2002/011891 patent/WO2002091991A2/en not_active Ceased
-
2008
- 2008-11-13 US US12/270,110 patent/US20090068104A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1067492A1 (en) | 2005-04-15 |
| EP1414299B1 (en) | 2011-05-04 |
| CA2447391C (en) | 2012-08-28 |
| WO2002091991A2 (en) | 2002-11-21 |
| EP1414299A2 (en) | 2004-05-06 |
| US20040167061A1 (en) | 2004-08-26 |
| ATE507844T1 (de) | 2011-05-15 |
| CA2447391A1 (en) | 2002-11-21 |
| DE60239938D1 (de) | 2011-06-16 |
| WO2002091991A3 (en) | 2004-02-19 |
| EP1414299A4 (en) | 2005-06-22 |
| CN1529551A (zh) | 2004-09-15 |
| JP2005514322A (ja) | 2005-05-19 |
| CN1307200C (zh) | 2007-03-28 |
| US20090068104A1 (en) | 2009-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE332918T1 (de) | Neoglycoproteine | |
| WO2004018000A3 (en) | Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents | |
| EA200501810A1 (ru) | Композиция конъюгированного лекарственного средства | |
| EA200800952A1 (ru) | Конъюгаты антитело-лекарство и способы применения | |
| ATE473759T1 (de) | Bifunktionelle moleküle sowie darauf basierende therapien. | |
| WO2005116255A3 (en) | Aptamer-toxin molecules and method for using same | |
| MXPA02010801A (es) | Agentes diagnosticos, de representacion y terapeuticos cationicos asociados con sitios vasculares activados. | |
| ATE478094T1 (de) | Für das fibroblastenaktivierungsprotein spezifische antikörpermoleküle und immunkonjugate,die diese enthalten | |
| NZ288883A (en) | Conjugates comprising coagulation factors | |
| ATE304709T1 (de) | Substanzen mit verzweigten linkermolekülen | |
| DK1180121T3 (da) | Langtidsvirkende insulinotrope peptider | |
| WO1997029779A3 (en) | EGF-Genistein conjugates for the treatment of cancer | |
| ATE368054T1 (de) | Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität | |
| DE69910216D1 (de) | Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung | |
| AR035977A1 (es) | Inmunoconjugados de anticuerpos cd44 citotoxicos. | |
| NO975547L (no) | Vaksiner med modifiserte meningokokk/polysakkarid-konjugater | |
| WO2008101214A3 (en) | Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders | |
| EE03858B1 (et) | Konjugaadid, nende kasutamine eesnäärmevähi ravimites, farmatseutiline kompositsioon ja selle valmistamine | |
| WO2004013307A3 (en) | Compounds for targeting hepatocytes | |
| PL373511A1 (pl) | Zasadniczo homogeniczny biooddziaływujący materiał o wstępnie określonym stosunku składnika biooddziaływującego do składnika ukierunkowanego komórkowo, sposób wytwarzania takiego materiału oraz sposób jego stosowania | |
| WO2002087497A3 (en) | Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use | |
| WO2003035011A8 (en) | Multidrug multiligand conjugates for targeted drug delivery | |
| HUP0100350A3 (en) | Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use | |
| WO2004053054A3 (en) | Nk cell receptor conjugates for treating malignancies | |
| WO2005002516A3 (en) | Leukocyte internalized peptide-drug conjugates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |